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Abstract: The present work is devoted to the development of a diagnostic model based on 
photodynamic therapy to obtain an estimation of a skin tumor depth from the measurement of the 
photosensitizer fluorescence emission.   




Photodynamic Therapy (PDT) [1] is commonly known for its excellent therapeutic properties to treat non melanoma 
skin cancers and cancer precursor diseases although its diagnostic capability is fairly unexploited. The 
photosensitizer fluorescence diagnosis or photodynamic diagnosis allows a macroscopic evaluation and the 
delimitation of the tumor superficial margins [2]. However a microscopic evaluation in depth requires the use of 
other techniques such as confocal and tomographic techniques. The present work is devoted to the application of a 
PDT based diagnostic model to obtain an estimation of a skin tumor depth from the measurement of the 
photosensitizer fluorescence emission [3]. The obtained results so far allow us to know the photosensitizer 
fluorescence emission during the PDT treatment and constitute a first approach to achieve a future model that 
permits to diagnose the extent in depth of a tumor using superficial photosensitizer fluorescence measurements.  
2.  Photodynamic diagnostic modeling  
The PDT based diagnostic model takes into account the optical radiation distribution, an inhomogeneous topical 
photosensitizer distribution in the target tissue, the photochemical interaction that takes place between the optical 
radiation and the photosensitized tissue and the photosensitizer fluorescence emission. In order to obtain the 
distribution of light in a three dimensional tissue we used the Radiation Transport Theory (RTT) [4] in a steady-state 
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The excitation optical radiation distribution was obtained by means of a Monte Carlo approach [5] while the 
photosensitizer fluorescence emission generated was obtained taking into account the spatial temporal variation of 
photosensitizer molecules during the photochemical interaction, the excitation photon density and the fluorescence 
quantum yield. Thus the photosensitizer fluorescence power density generated was calculated as: 
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= λ  is the photon energy at the fluorescence emission wavelength, h  is the Planck's constant, 
c  is the speed of light in vacuum and  emλ  is the fluorescence emission wavelength. 
 
The final inhomogeneous photosensitizer distribution in the target tissue during the incubation period was obtained 
by means of the Fick's law shown in equation (3), where J  is the flux vector indicating the direction and magnitude 
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The temporal evolution of the photosensitizer precursor concentration, M ,  for each depth in the tissue sample can 
be calculated as, [6]: 
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where oM  is the concentration of the photosensitizer precursor in the skin surface at t 0= , z is the distance from 
the corneal layer located at z 0=  , K is the permeability of the stratum corneum and τ  is the relaxation time of the 
precursor as a consequence of the generation of the photosensitizer and other processes (lymphatic flow and blood 
perfusion). The concentration of photoactive substance, 0S , accumulated in the tissue was obtained as expressed in 
(5), assuming that the photosensitizer relaxation time is fast compared to the photosensitizer precursor diffusion 
time, 
p tτ << . Therefore the concentration of photoactive compound, [6], is proportional to the instantaneous value 
of the precursor concentration, pε  is the yield of the conversion process and pa→τ  the relaxation time of the 
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The temporal evolution of the photosensitizer molecules and other molecular components involved in the 
photochemical interaction between the optical radiation and the photosensitized tissue was obtained by means of a 
photochemical model [7, 8]. This model is based on a stiff differential equations system (equations 6 to 11) which 
takes into account the energetic transitions of the photosensitizer during a Type II reaction. The solutions of the stiff 
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 3.  Results and discussion  
Figure 1 shows the fluorescence power density generated by the photosensitizer molecules at different temporal 
points during the photodynamic treatment. As it can be observed, the fluorescence decreases more rapidly in shallow 
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areas where a greater amount of energy is deposited and the photobleaching effects appear first. As the optical 
irradiation is applied during the progression of treatment, most of the fluorescence comes from the inner layers of 
the tumor.  
 
Fig. 1. Photosensitizer fluorescence power density (W/cm3) generated at a) 5 s, b) 50 s, c) 120 s and d) 150 s during PDT 
 
The results shown correspond to a basal cell carcinoma tumor depth of 3 mm, irradiated with a cylindrical laser 
beam with a radius of 0.3 cm perpendicular to the tumor surface and a fixed irradiance of 100 mW/cm
2
. The optical 
properties used at the excitation wavelength (635 nm) for the tumor were the absorption coefficient, µa=1.5 cm
−1
, the 
scattering coefficient, µs=104.76 cm
−1
, the anisotropy of scattering, g=0.79 and the index of refraction, n=1.5, 
whereas the healthy tissue beneath the tumor was considered muscle with an index of refraction of 1.37. The 
photosensitizer precursor Methyl Aminolevulinate (MAL) was used to model its diffusion through the tumor tissue 
and to obtain the photosensitizer Protoporphyrin IX (PpIX) endogenously generated during an incubation period of 3 
hours. In view of the results presented in Figure 1, the selective localization of the photoactive substance in the 
tumor and its ability to emit fluorescence coupled with the fact that the photosensitizer fluorescence comes mostly 
from the inner layers of the tumor as the excitation time increases, could be employed to get a relationship between 
the time period when fluorescence is emitted and the depth of the tumor. The model presented and these preliminary 
results will constitute the starting point of future works to develop a model based in the ability of the photosensitizer 
molecules to emit fluorescence applied in PDT with a diagnostic purpose instead of with a therapeutic one. The 
main objective of this diagnostic model based on PDT will be to estimate the depth of the tumor by means of the 
analysis of the time needed to get a significant decrease in the fluorescence.   
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